Profile data is unavailable for this security.
About the company
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
- Revenue in USD (TTM)260.81m
- Net income in USD20.48m
- Incorporated2000
- Employees408.00
- LocationDynavax Technologies Corp2100 Powell Street, Suite 720EMERYVILLE 94608United StatesUSA
- Phone+1 (510) 848-5100
- Fax+1 (510) 848-1327
- Websitehttps://www.dynavax.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arcus Biosciences Inc | 263.00m | -270.00m | 1.62bn | 577.00 | -- | 2.87 | -- | 6.18 | -3.15 | -3.15 | 3.06 | 6.17 | 0.2153 | -- | 6.83 | 455,805.90 | -22.10 | -15.85 | -26.63 | -18.25 | -- | -- | -102.66 | -103.46 | -- | -- | 0.0768 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
| Travere Therapeutics Inc | 203.45m | -348.96m | 1.63bn | 380.00 | -- | -- | -- | 8.02 | -4.52 | -4.56 | 2.63 | -0.3909 | 0.3043 | 0.7192 | 10.24 | 535,386.80 | -52.19 | -36.95 | -69.25 | -44.77 | 95.21 | 95.92 | -171.52 | -165.79 | 1.68 | -- | 1.09 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
| Xencor Inc | 85.16m | -198.24m | 1.63bn | 280.00 | -- | 2.25 | -- | 19.15 | -3.20 | -3.20 | 1.37 | 10.35 | 0.0967 | -- | 2.61 | 304,157.20 | -22.89 | -3.70 | -24.90 | -4.12 | -- | -- | -236.81 | -15.92 | -- | -- | 0.0243 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Kiniksa Pharmaceuticals Ltd | 384.10m | -9.07m | 1.66bn | 297.00 | -- | 3.80 | -- | 4.33 | -0.1584 | -0.1584 | 5.28 | 6.06 | 0.7398 | 1.94 | 27.51 | 1,293,259.00 | -1.75 | -16.49 | -2.04 | -18.72 | 86.31 | -- | -2.36 | -53.64 | 2.95 | -- | 0.00 | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
| Bicycle Therapeutics PLC (ADR) | 36.90m | -166.28m | 1.68bn | 284.00 | -- | 2.02 | -- | 45.51 | -3.28 | -3.28 | 0.7163 | 12.04 | 0.0451 | -- | 0.9806 | 129,922.50 | -20.33 | -29.45 | -22.03 | -32.98 | -- | -- | -450.64 | -571.36 | -- | -- | 0.0002 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
| ARS Pharmaceuticals Inc | 500.00k | -44.84m | 1.70bn | 23.00 | -- | 7.88 | -- | 3,391.02 | -0.466 | -0.466 | 0.0052 | 2.22 | 0.0021 | -- | -- | 20,833.33 | -18.66 | -20.37 | -19.33 | -21.32 | -- | -- | -8,968.40 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
| BioCryst Pharmaceuticals Inc | 412.58m | -123.82m | 1.70bn | 536.00 | -- | -- | -- | 4.11 | -0.6073 | -0.6073 | 2.01 | -2.26 | 0.8136 | 0.4297 | 6.54 | 769,736.90 | -24.42 | -47.95 | -32.17 | -64.89 | 98.06 | 97.06 | -30.01 | -114.94 | 2.73 | -0.488 | 2.29 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
| Celldex Therapeutics, Inc. | 9.98m | -154.08m | 1.74bn | 160.00 | -- | 2.21 | -- | 174.31 | -2.57 | -2.57 | 0.164 | 11.85 | 0.0181 | -- | 18.07 | 62,350.00 | -27.93 | -29.65 | -29.53 | -31.42 | -- | -- | -1,544.48 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
| Intellia Therapeutics Inc | 43.09m | -522.28m | 1.78bn | 526.00 | -- | 1.85 | -- | 41.26 | -5.45 | -5.45 | 0.4509 | 9.46 | 0.0357 | -- | 5.62 | 81,912.55 | -43.22 | -31.34 | -47.07 | -34.53 | -- | -- | -1,212.19 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
| Dynavax Technologies Corp | 260.81m | 20.48m | 1.79bn | 408.00 | 111.90 | 2.63 | 71.50 | 6.86 | 0.1221 | 0.1221 | 1.83 | 5.19 | 0.2563 | 0.80 | 4.36 | 639,242.60 | 2.01 | 4.16 | 2.14 | 5.71 | 82.85 | 64.83 | 7.85 | 9.19 | 12.34 | -- | 0.247 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
| Syndax Pharmaceuticals Inc | 16.00m | -297.06m | 1.86bn | 112.00 | -- | 5.09 | -- | 116.19 | -3.63 | -3.63 | 0.1949 | 4.28 | 0.0388 | -- | 3.60 | 142,857.10 | -72.01 | -27.90 | -81.78 | -30.15 | -- | -- | -1,856.64 | -324.34 | -- | -- | 0.00003 | -- | -- | -- | -40.19 | -- | -- | -- |
| Arvinas Inc | 161.10m | -308.60m | 1.93bn | 445.00 | -- | 3.29 | -- | 11.96 | -4.79 | -4.79 | 2.38 | 8.53 | 0.1448 | -- | 14.01 | 362,022.50 | -27.73 | -22.01 | -37.81 | -26.47 | -- | -- | -191.56 | -316.55 | -- | -- | 0.001 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Viridian Therapeutics Inc | 288.00k | -228.06m | 1.96bn | 96.00 | -- | 4.98 | -- | 6,815.50 | -4.25 | -4.25 | 0.0053 | 8.29 | 0.0006 | -- | 5.65 | 3,063.83 | -48.67 | -55.59 | -52.32 | -60.32 | -- | -- | -79,185.77 | -5,678.12 | -- | -- | 0.0372 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
| Disc Medicine Inc | 0.00 | -91.00m | 1.98bn | 74.00 | -- | 4.05 | -- | -- | -3.66 | -3.66 | 0.00 | 16.45 | 0.00 | -- | -- | 0.00 | -20.35 | -- | -21.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to Dynavax Technologies Corp's reporting currency: US Dollar USD
65.33%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Jun 2024 | 20.24m | 15.45% |
| Deep Track Capital LPas of 22 Oct 2024 | 17.79m | 13.58% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 9.04m | 6.90% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 7.69m | 5.87% |
| Kynam Capital Management LPas of 30 Jun 2024 | 7.08m | 5.41% |
| Federated Global Investment Management Corp.as of 30 Jun 2024 | 7.01m | 5.35% |
| Chicago Capital LLCas of 30 Sep 2024 | 5.49m | 4.19% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Jun 2024 | 4.49m | 3.43% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 3.68m | 2.81% |
| Geode Capital Management LLCas of 30 Jun 2024 | 3.09m | 2.36% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
